News | January 03, 2012

Maquet Cardiovascular Exclusive U.S. Distributor of Novadaq CO2 Heart Laser

January 3, 2012 – Novadaq Technologies Inc., a developer of real-time imaging systems for use in the operating room, and Maquet  Cardiovascular, a manufacturer of products for cardiac surgery, vascular intervention and cardiac support, announced that the companies have signed an agreement naming Maquet Cardiovascular as the exclusive distributor of Novadaq's CO2 Heart Laser systems and procedure kits in the United States.

The CO2 Heart Laser System for transmyocardial revascularization (TMR) is indicated for use in patients suffering from severe angina that is not amenable to traditional medical or coronary revascularization therapies. During the TMR procedure, the CO2 Heart Laser creates small channels in the heart tissue, which stimulate improvements in blood flow to regions of the heart.

"This distribution agreement with Novadaq for the CO2 Heart Laser fits well into Maquet 's current portfolio of cardiac surgery products and allows us to provide our customers additional therapies to meet their patients' needs," said Raoul Quintero, president, U.S. Sales and Service Organization, Maquet Medical Systems.

"The alliance with Maquet represents Novadaq's fourth commercial agreement with a market leader," said Arun Menawat, M.D., president and CEO, Novadaq.

For more information: www.maquet.com, www.novadaq.com

Related Content

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Overlay Init